Cimzia certolizumab pegol: Completed Phase III enrollment

Dermira completed enrollment of about 225 patients in the double-blind, placebo-controlled, international Phase III CIMPASI-1 trial evaluating subcutaneous Cimzia for up to 48 weeks. Patients will receive 400 mg Cimzia every 2 weeks or 400 mg at weeks 0, 2 and 4 followed by 200 mg every 2 weeks. ...